piperazine-1,4-dicarboxylic acid tert-butyl ester butyl ester | 1073554-07-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: piperazine-1,4-dicarboxylic acid tert-butyl ester butyl ester
• 英文别名: piperazine-1,4-dicarboxylic acid butyl ester tert-butyl ester；Piperazine-1,4-dicarboxylic acid tert-butyl ester butyl ester；1-O-butyl 4-O-tert-butyl piperazine-1,4-dicarboxylate
• CAS: 1073554-07-0
• 化学式: C₁₄H₂₆N₂O₄
• 分子量: 286.371
• InChiKey: TUALBCZNOWMBRL-UHFFFAOYSA-N

物化性质

• 沸点：
  364.3±17.0 °C(Predicted)
• 密度：
  1.089±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  20
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  59.1
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  piperazine-1,4-dicarboxylic acid tert-butyl ester butyl ester 在 四(三苯基膦)钯 、 5%-palladium/activated carbon 盐酸 、 potassium phosphate 、 草酰氯 、 氢气 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 甲醇 、 二氯甲烷 、 乙腈 为溶剂， 反应 26.08h， 生成 4-{(S)-4-tert-butoxycarbonyl-2-[(6-cyclopropyl-2-phenyl-pyrimidine-4-carbonyl)-amino]-butyryl}-piperazine-1-carboxylic acid butyl ester
  参考文献：
  名称：

  [EN] 2-PHENYL-4-CYCLOPROPYL-PYRIMIDINE DERIVATIVES
  [FR] DÉRIVÉS DE 2-PHÉNYL-4-CYCLOPROPYL-PYRIMIDINE

  摘要：

  本发明涉及2-苯基-4-环丙基-嘧啶衍生物及其作为P2Y12受体拮抗剂在治疗和/或预防外周血管、内脏-、肝脏和肾脏血管、心血管和脑血管疾病或与血小板聚集有关的疾病或病况中的应用，包括人类和其他哺乳动物中的血栓形成。

  公开号：

  WO2009125365A1
• 作为产物：
  描述：

  氯甲酸丁酯 、 N-Boc-哌嗪 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 生成 piperazine-1,4-dicarboxylic acid tert-butyl ester butyl ester
  参考文献：
  名称：

  [EN] 2-PHENYL-4-CYCLOPROPYL-PYRIMIDINE DERIVATIVES
  [FR] DÉRIVÉS DE 2-PHÉNYL-4-CYCLOPROPYL-PYRIMIDINE

  摘要：

  本发明涉及2-苯基-4-环丙基-嘧啶衍生物及其作为P2Y12受体拮抗剂在治疗和/或预防外周血管、内脏-、肝脏和肾脏血管、心血管和脑血管疾病或与血小板聚集有关的疾病或病况中的应用，包括人类和其他哺乳动物中的血栓形成。

  公开号：

  WO2009125365A1

文献信息

• SUBSTITUTED 2-PHENYL-PYRIDINE DERIVATIVES
  申请人：Caroff Eva

  公开号：US20110046089A1

  公开（公告）日：2011-02-24

  The present invention relates to compounds of formula I wherein R 1 , R 2 , R 4 , R 5 , R a , R b , n, W and Z are as defined in the application, their preparation and their use as P2Y 12 receptor antagonists in the treatment and/or prevention of peripheral vascular, of visceral-, hepatic- and renal-vascular, of cardiovascular and of cerebrovascular diseases or conditions associated with platelet aggregation, including thrombosis in humans and other mammals.

  本发明涉及式I化合物的制备及其用途，式中R1、R2、R4、R5、Ra、Rb、n、W和Z的定义如申请中所述，以及它们作为P2Y12受体拮抗剂用于治疗和/或预防外周血管、内脏血管、肝脏血管和肾脏血管、心血管和脑血管疾病或与血小板聚集相关状况的用途，包括人类和其他哺乳动物中的血栓症。
• [EN] SUBSTITUTED 2-PHENYL-PYRIDINE DERIVATIVES<br/>[FR] DÉRIVÉS DE 2-PHÉNYL-PYRIDINE SUBSTITUÉS
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2009125366A1

  公开（公告）日：2009-10-15

  The present invention relates to compounds of formula (I) wherein R1, R2, R4, R5, Ra, Rb, n, W and Z are as defined in the application, their preparation and their use as P2Y12 receptor antagonists in the treatment and/or prevention of peripheral vascular, of visceral-, hepatic- and renal-vascular, of cardiovascular and of cerebrovascular diseases or conditions associated with platelet aggregation, including thrombosis in humans and other mammals.

  本发明涉及式(I)化合物，其中R1、R2、R4、R5、Ra、Rb、n、W和Z如申请中所定义，它们的制备以及它们作为P2Y12受体拮抗剂用于治疗和/或预防外周血管、内脏血管、肝脏血管和肾脏血管、心血管和脑血管疾病或与血小板聚集相关的状况的应用，包括人类和其他哺乳动物中的血栓。
• 2-PHENYL-4-CYCLOPROPYL-PYRIMIDINE DERIVATIVES
  申请人：Caroff Eva

  公开号：US20110028484A1

  公开（公告）日：2011-02-03

  The present invention relates to 2-phenyl-4-cyclopropyl-pyrimidine derivatives and their use as P2Y 12 receptor antagonists in the treatment and/or prevention of peripheral vascular, of visceral-, hepatic- and renal-vascular, of cardiovascular and of cerebrovascular diseases or conditions associated with platelet aggregation, including thrombosis in humans and other mammals.

  本发明涉及2-苯基-4-环丙基-嘧啶衍生物及其作为P2Y12受体拮抗剂在治疗和/或预防外周血管、内脏-、肝脏和肾脏血管、心血管和脑血管疾病或与血小板聚集有关的疾病或病况中的应用，包括人类和其他哺乳动物中的血栓形成。
• QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS
  申请人：Nazaré Marc

  公开号：US20100135999A1

  公开（公告）日：2010-06-03

  The present invention relates to compounds of the formula I, in which R 1 ; R 2 ; R 3 ; R 4 ; R 5 ; R 6 ; Z; A; B; E; X; Q; J; V; G and M have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong anti-aggregating effect on platelets and thus an anti-thrombotic effect and are suitable e.g. for the therapy and prophylaxis of cardio-vascular disorders like thromboembolic diseases or restenoses. They are reversible antagonists of the platelet ADP receptor P2Y12, and can in general be applied in conditions in which an undesired activation of the platelet ADP receptor P2Y12 is present or for the cure or prevention of which an inhibition of the platelet ADP receptor P2Y12 is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.

  本发明涉及公式I的化合物，其中R1; R2; R3; R4; R5; R6; Z; A; B; E; X; Q; J; V; G和M具有所述声明中指示的含义。公式I的化合物是有价值的药理活性化合物。它们对血小板具有强烈的抗聚集作用，从而具有抗血栓作用，适用于治疗和预防心血管疾病，如血栓栓塞病或再狭窄。它们是血小板ADP受体P2Y12的可逆拮抗剂，通常适用于存在不良激活血小板ADP受体P2Y12的情况，或者治愈或预防需要抑制血小板ADP受体P2Y12的情况。此外，本发明还涉及制备公式I化合物的方法，它们的用途，特别是作为药物中的活性成分，以及包含它们的制药制剂。
• Quinoline-carboxamide derivatives as P2Y12 antagonists
  申请人：Nazare Marc

  公开号：US08669266B2

  公开（公告）日：2014-03-11

  The present invention relates to compounds of the formula I, in which R1; R2; R3; R4; R5; R6; Z; A; B; E; X; Q; J; V; G and M have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong anti-aggregating effect on platelets and thus an anti-thrombotic effect and are suitable e.g. for the therapy and prophylaxis of cardio-vascular disorders like thromboembolic diseases or restenoses. They are reversible antagonists of the platelet ADP receptor P2Y12, and can in general be applied in conditions in which an undesired activation of the platelet ADP receptor P2Y12 is present or for the cure or prevention of which an inhibition of the platelet ADP receptor P2Y12 is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.

  本发明涉及公式I的化合物，其中R1; R2; R3; R4; R5; R6; Z; A; B; E; X; Q; J; V; G和M具有所述权利要求中指定的含义。公式I的化合物是有价值的药理活性化合物。它们在血小板上表现出强烈的抗聚集作用，因此具有抗血栓作用，适用于治疗和预防心血管疾病，如血栓栓塞病或再狭窄。它们是血小板ADP受体P2Y12的可逆拮抗剂，并且通常可以应用于存在不希望的血小板ADP受体P2Y12激活或需要抑制血小板ADP受体P2Y12的治疗或预防的情况。此外，本发明还涉及公式I的化合物的制备方法，它们的使用，特别是作为药物的活性成分，以及包含它们的药物制剂。